Ozempic vs Wegovy vs Mounjaro vs Zepbound: Differences, Evidence, Safety and Access (2026)

By Dr. Frank Yap, MD, One Day Media Network · Published 2026-10-04 · Last updated 2026-10-04 · Reading time about 12 minutes

Medical and affiliate disclosure

This article is educational and is not medical advice. It synthesizes published trials and regulatory information and is not a substitute for a licensed prescriber who knows your history. Prescription GLP-1 medicines are not suitable for everyone. The One Day Media Network participates in affiliate programs (The Wellness Company and Amazon Associates). This article contains no affiliate links and no product is recommended for purchase.

Quick Answer

Ozempic and Wegovy are the same drug (semaglutide); Mounjaro and Zepbound are the same drug (tirzepatide). Ozempic and Mounjaro are labeled for type 2 diabetes, while Wegovy and Zepbound are labeled for weight management. In the head-to-head SURMOUNT-5 trial, tirzepatide produced 20.2% weight loss versus 13.7% for semaglutide at 72 weeks. The right choice depends on diagnosis, coverage, tolerability and other conditions.

In this article

• Are these four drugs different or the same?
• Side-by-side comparison table
• Which produces more weight loss?
• Heart, kidney, liver and sleep apnea indications
• Side effects and who should avoid them
• What happens when you stop?
• Pill options: Wegovy pill and Foundayo
• Cost and access, including Malaysia and Singapore
• How clinicians think about choosing
• AI personalization guide
• Frequently asked questions
• References

Are Ozempic, Wegovy, Mounjaro and Zepbound different drugs?

There are two active ingredients, each sold under two brand names. Semaglutide (Novo Nordisk) is sold as Ozempic and Wegovy. Tirzepatide (Eli Lilly) is sold as Mounjaro and Zepbound. The brand pairs share a molecule but differ in labeled indication, maximum dose, pen design and often insurance coverage.

Semaglutide activates the GLP-1 receptor. Tirzepatide activates both the GIP and GLP-1 receptors, which is why it is called a dual agonist. Whether the added GIP activity fully explains tirzepatide's larger average effect is still debated, and the trial data below show the outcome difference rather than prove the mechanism.

How do the four compare side by side?

The table summarizes US labeling and headline trial results as of October 2026. Always confirm current labeling in the official prescribing information, because indications and doses are updated over time.

	Ozempic	Wegovy	Mounjaro	Zepbound
Active ingredient	Semaglutide	Semaglutide	Tirzepatide	Tirzepatide
Manufacturer	Novo Nordisk	Novo Nordisk	Eli Lilly	Eli Lilly
Receptor action	GLP-1	GLP-1	GIP and GLP-1	GIP and GLP-1
Core US indication	Type 2 diabetes	Chronic weight management	Type 2 diabetes	Chronic weight management
Other labeled uses	Lower major cardiovascular events in T2D with heart disease; slow kidney disease progression in T2D with CKD	Lower major cardiovascular events in adults with obesity and established heart disease; MASH with moderate to advanced fibrosis	None beyond glycemic control at the time of writing	Obstructive sleep apnea in adults with obesity
Dosing	Once weekly injection	Once weekly injection (a daily Wegovy pill also exists)	Once weekly injection	Once weekly injection
Maximum standard weekly dose	2 mg	2.4 mg	15 mg	15 mg
Pivotal weight-loss result	Not the labeled use; lower doses than Wegovy	About 14.9% at 68 weeks (STEP 1)	Not the labeled use for weight	About 20.9% at 72 weeks on 15 mg (SURMOUNT-1)

Evidence tier for this table: CEBM Level 2 (individual randomized trials) for efficacy figures; regulatory facts come from FDA labeling. Figures are from different trials with different populations, so cross-trial comparison is indirect. The head-to-head trial is covered next.

Which produces more weight loss: semaglutide or tirzepatide?

Tirzepatide produced greater average weight loss than semaglutide in the only large head-to-head trial. In SURMOUNT-5, an open-label randomized trial in 751 adults with obesity or overweight plus a weight-related condition and no diabetes, average weight change at 72 weeks was -20.2% with tirzepatide versus -13.7% with semaglutide (about 22.8 kg versus 15.0 kg). Waist circumference fell 18.4 cm versus 13.0 cm. Roughly 31.6% on tirzepatide lost at least 25% of body weight versus 16.1% on semaglutide.

Adverse-event rates were similar between groups, at about 77% for tirzepatide and 79% for semaglutide for at least one event. Women lost more than men in both arms, so the average understates what some individuals achieve and overstates it for others.

Trial	Drug and dose	Population	Result	CEBM level
STEP 1 (Wilding 2021)	Semaglutide 2.4 mg weekly	Obesity, no diabetes, 68 weeks	About 14.9% weight loss vs 2.4% placebo	Level 2 (RCT)
SURMOUNT-1 (Jastreboff 2022)	Tirzepatide 5, 10, 15 mg weekly	Obesity, no diabetes, 72 weeks	15.0% (5 mg) up to 20.9% (15 mg) vs 3.1% placebo	Level 2 (RCT)
SURMOUNT-5 (Aronne 2025)	Tirzepatide vs semaglutide, maximum tolerated dose	751 adults, obesity, no diabetes, 72 weeks, open-label	20.2% vs 13.7%; waist 18.4 vs 13.0 cm	Level 2 (RCT, head-to-head)
OASIS 4 (oral semaglutide 25 mg daily)	Wegovy pill	Obesity or overweight, 64 weeks	16.6% with full adherence vs 2.7% placebo	Level 2 (RCT)

Weight loss is not the only outcome that matters. Greater weight reduction tends to bring greater improvement in blood pressure, triglycerides and glycemic markers, but cardiovascular outcome evidence differs between the two molecules, as described below.

Which drug has evidence for the heart, kidneys, liver and sleep apnea?

Semaglutide has the longer record in hard cardiovascular outcomes; tirzepatide has a specific labeled sleep apnea indication. The SELECT trial enrolled 17,604 adults with overweight or obesity and established cardiovascular disease but no diabetes. Semaglutide 2.4 mg lowered major adverse cardiovascular events by about 20% (hazard ratio 0.80) over a mean of roughly 40 months, which supported the Wegovy cardiovascular indication.

• Kidney: Ozempic carries a US indication to slow kidney disease progression in people with type 2 diabetes and chronic kidney disease, based on the FLOW trial. CEBM Level 2.
• Liver: Wegovy has US approval for MASH (metabolic dysfunction-associated steatohepatitis) with moderate to advanced fibrosis, an accelerated approval that depends on confirmatory outcome data. CEBM Level 2, surrogate endpoint.
• Sleep apnea: Zepbound is approved for moderate to severe obstructive sleep apnea in adults with obesity, based on the SURMOUNT-OSA trials. CEBM Level 2.
• Tirzepatide cardiovascular outcomes: Outcome data are accumulating but are less mature than the semaglutide record. Check current labeling for any update.

What are the side effects, and who should avoid these medicines?

Side effects are broadly similar across all four products because they share a drug class. The most common are nausea, vomiting, diarrhea, constipation and abdominal discomfort, usually worst during dose escalation and often easing later. Slow titration is the main strategy used to improve tolerability.

Less common and serious risks

• Gallbladder disease (gallstones, cholecystitis), particularly with rapid weight loss.
• Pancreatitis. Persistent severe abdominal pain, with or without vomiting, needs urgent assessment.
• Dehydration from vomiting or diarrhea, which can injure the kidneys.
• Delayed gastric emptying, with labeling advice to tell anesthesia teams about use before procedures because of aspiration risk.
• Hypoglycemia, mainly when combined with insulin or sulfonylureas in people with diabetes.
• Diabetic retinopathy complications in people with type 2 diabetes and existing retinopathy, which warrants eye monitoring when glucose falls quickly.
• Tirzepatide can reduce the effectiveness of oral hormonal contraceptives; labeling advises a non-oral or added barrier method around initiation and each dose increase.

Boxed warning (all four products)

Semaglutide and tirzepatide products carry a boxed warning about thyroid C-cell tumors seen in rodents. They are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). They are also not used in pregnancy. Seek urgent care for a neck lump, trouble swallowing, persistent hoarseness, or severe abdominal pain.

Evidence tier: CEBM Level 2 for adverse-event rates from pivotal trials; labeling statements reflect regulatory review of the whole evidence base.

What happens to your weight if you stop?

Most people regain a substantial portion of lost weight after stopping, which is why these are generally treated as long-term therapies. In the STEP 1 extension, participants who stopped semaglutide regained about two thirds of their prior loss within a year. In SURMOUNT-4, adults who switched from tirzepatide to placebo regained about 14% of body weight while those who continued lost a further 5.5%. CEBM Level 2.

Lifestyle, resistance training and adequate protein intake are commonly discussed alongside treatment to help preserve lean mass, but whether any specific program prevents regain after stopping is not established by these trials.

Are there pill versions? Wegovy pill and Foundayo (orforglipron)

Yes. Two daily oral GLP-1 products for obesity are now FDA-approved in the US. The FDA approved the Wegovy pill (oral semaglutide 25 mg once daily) on December 22, 2025, based on the OASIS program and the SELECT trial, and it reached US pharmacies in early January 2026 (Novo Nordisk announcement). The FDA approved Lilly's Foundayo (orforglipron) on April 1, 2026, a small-molecule oral GLP-1 that can be taken at any time of day without food or water restrictions (Lilly announcement).

Product	Form	Trial weight loss (headline)	Note
Wegovy pill	Daily oral semaglutide 25 mg	16.6% with full adherence at 64 weeks (OASIS 4)	Taken under specific fasting instructions per label
Foundayo (orforglipron)	Daily oral small molecule	About 12.4% at the highest dose in the ATTAIN program	Any time of day, no food or water restrictions
Zepbound injection	Weekly injection	About 20.9% at 15 mg (SURMOUNT-1)	Highest average loss among these options in trials

Evidence tier: CEBM Level 2 per product; the pills have not been compared head-to-head with injections in a randomized trial in this summary.

How much do they cost, and are they available in Malaysia and Singapore?

Prices vary widely by payer, dose and pharmacy, and they change often. In the US, list prices run roughly US$1,000 to US$1,350 per month, while manufacturer self-pay programs (NovoCare Pharmacy for semaglutide, LillyDirect for tirzepatide) were reported in 2026 at roughly US$200 to US$450 per month depending on product and dose. With qualifying commercial insurance, savings cards can lower copays substantially. Treat every figure here as a snapshot and confirm on the manufacturer or pharmacy site before deciding.

Malaysia and Singapore

Regulatory status differs by country, brand and indication, and clinic websites report it inconsistently. Reports indicate that Ozempic and Mounjaro are available by prescription in both markets and that Mounjaro received NPRA approval in Malaysia in August 2025, while Wegovy and Zepbound availability varies and has changed over time. Verify the current registered brands with the NPRA (Malaysia), the HSA (Singapore), or a licensed local prescriber. Private-pay prices are generally not subsidized for weight management.

Compounded or unregulated “semaglutide” and “tirzepatide” products are not equivalent to the approved brands. Avoid products sold without a prescription or from unverified online sellers.

How do clinicians think about choosing between them?

The decision is driven by diagnosis, goals, coexisting conditions, tolerability and coverage, not brand preference. The questions below are the ones a prescriber is likely to work through. They are a discussion guide, not a recommendation.

Situation	What tends to matter
Type 2 diabetes is the main problem	Ozempic or Mounjaro are labeled for it; both also lower weight. Ozempic has labeled cardiovascular and kidney indications in T2D.
Obesity without diabetes, maximum weight reduction is the goal	Tirzepatide (Zepbound) produced the larger average loss in head-to-head data.
Obesity with established heart disease	Semaglutide (Wegovy) has randomized cardiovascular outcome data (SELECT) and a labeled indication.
Obstructive sleep apnea with obesity	Zepbound has a labeled indication.
MASH with significant fibrosis	Wegovy has a labeled accelerated-approval indication.
Needle avoidance	Oral options exist (Wegovy pill, Foundayo) with lower average loss in trials.
Medullary thyroid cancer or MEN 2 history, pregnancy, pancreatitis history	Typically contraindicated or requires specialist judgment for the whole class.
Cost or insurance restrictions	Formulary status and self-pay programs often decide what is practical.

How can you use this article with Claude, ChatGPT and Gemini?

AI assistants are useful for preparing questions and organizing information, not for choosing a prescription. Do not paste identifying details, lab reports or full medical records into a general-purpose assistant. Describe your situation in general terms and always verify drug facts against the prescribing information.

Assistant	Best use here	Example prompt
Claude	Structuring a clinic-visit question list; explaining trial design and limitations	“Using the SURMOUNT-5 and SELECT trials, write ten questions I should ask my doctor about semaglutide vs tirzepatide for someone with obesity and high blood pressure.”
ChatGPT	Plain-language summaries and comparison tables you can edit	“Summarize the differences between Wegovy and Zepbound in a table for a non-medical reader, and flag where evidence is head-to-head vs cross-trial.”
Gemini	Cross-checking against Google-indexed regulatory pages	“List the current FDA-labeled indications for Ozempic, Wegovy, Mounjaro and Zepbound and cite the label sections.”

Ask any assistant to name its sources and the date of each, and treat unsourced numbers as unverified.

Frequently asked questions

Is Ozempic the same as Wegovy?

Both contain semaglutide and are made by Novo Nordisk. They differ in labeled use, dose range and pens. Ozempic (up to 2 mg weekly) is labeled for type 2 diabetes, while Wegovy (2.4 mg weekly) is labeled for chronic weight management and related indications. Using Ozempic for weight loss is off-label.

Is Mounjaro the same as Zepbound?

Both contain tirzepatide and are made by Eli Lilly. Mounjaro is labeled for type 2 diabetes. Zepbound is labeled for chronic weight management and for obstructive sleep apnea in adults with obesity. The doses overlap, with a top weekly dose of 15 mg for each.

Which works better for weight loss: semaglutide or tirzepatide?

In SURMOUNT-5, a head-to-head open-label randomized trial of 751 adults with obesity, tirzepatide produced 20.2% average weight loss versus 13.7% for semaglutide at 72 weeks. Individual results vary, and the trial excluded people with type 2 diabetes, so results may differ in other groups.

Can Ozempic or Mounjaro be used for weight loss?

Clinicians sometimes prescribe them off-label for weight loss, but their approved indication is type 2 diabetes. Insurance often will not cover off-label use, and the weight-management brands (Wegovy, Zepbound) carry trial-tested weight-loss dosing and labeling. Any such decision belongs with a licensed prescriber.

Will I regain weight if I stop?

Most people regain a substantial part of the lost weight after stopping. In the STEP 1 extension, participants regained about two thirds of their prior loss within a year of stopping semaglutide. In SURMOUNT-4, people switched from tirzepatide to placebo regained weight, while those who continued kept losing.

What are the most common side effects?

Gastrointestinal effects dominate across all four: nausea, vomiting, diarrhea and constipation, mostly during dose escalation. Less common risks include gallbladder disease, pancreatitis and dehydration-related kidney injury. All four carry a boxed warning about thyroid C-cell tumors in rodents.

Is there a pill version?

Yes. The FDA approved the once-daily Wegovy pill (oral semaglutide 25 mg) on December 22, 2025. Lilly's once-daily Foundayo (orforglipron) was approved on April 1, 2026. Both are separate products from the weekly injections compared here, with lower average weight loss in trials than tirzepatide injections.

Are these drugs available in Malaysia and Singapore?

Registration differs by country, brand and indication, and it changes over time. Check current status with the National Pharmaceutical Regulatory Agency (NPRA) in Malaysia, the Health Sciences Authority (HSA) in Singapore, or a licensed local prescriber before assuming that a specific brand is available.

References and sources

1. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021. doi:10.1056/NEJMoa2032183
2. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022. doi:10.1056/NEJMoa2206038
3. Aronne LJ et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med. 2025. doi:10.1056/NEJMoa2416394. Summary: American College of Cardiology journal scan
4. Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023. doi:10.1056/NEJMoa2307563
5. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022.
6. Aronne LJ et al. Continued treatment with tirzepatide for maintenance of weight reduction (SURMOUNT-4). JAMA. 2024.
7. Novo Nordisk. Wegovy pill approved in the US as first oral GLP-1 for weight management. 22 December 2025. novonordisk.com
8. Eli Lilly. FDA approves Foundayo (orforglipron). April 2026. investor.lilly.com
9. FDA prescribing information for Ozempic, Wegovy, Mounjaro and Zepbound via Drugs@FDA. Confirm current indications and doses here.

Evidence key (CEBM)

Level 1: systematic review of randomized trials. Level 2: individual randomized trial or strong observational study. Level 3: non-randomized cohort or case-control. Level 4: case series. Level 5: expert opinion or mechanism-based reasoning. Tiers in this article follow the Oxford CEBM scheme and describe study design, not how large or relevant the effect is for any one person.

Pricing, approvals and regional availability change frequently. This article was last updated on 4 October 2026 and will be revised on this same URL as new data and labeling changes appear. Always confirm current details with an official source and a licensed prescriber.